Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Febrile Neutropenia Clear all
Completed Phase 1Phase 2 Interventional Results available

A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer

NCT01619423
View directory record Official record
Conditions
Advanced Metastatic (Stage IV) Colorectal Cancer
Interventions
PledOx (2 µmol/kg), PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl)
Drug
Lead sponsor
Egetis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
La Jolla, California • Bethesda, Maryland • Chattanooga, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Sep 11, 2026, 2:10 AM EDT
Completed No phase listed Observational

Remote Temperature Data for Early Detection of Febrile Neutropenia

NCT05180838
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
BioSticker
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 11, 2026, 2:10 AM EDT
Completed No phase listed Observational

Biomarker To Evaluate Protein Profiles of Neutropenic Fever/Infection With Acute or Chronic Leukemias

NCT01144793
View directory record Official record
Conditions
Leukemia, Lymphocytic, Leukemia, Myeloid
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Sep 11, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 11, 2026, 2:10 AM EDT
Completed No phase listed Observational

Fatigue and Symptom Burden in Low-Risk Cancer Patients Undergoing Treatment for Febrile Neutropenia

NCT00503854
View directory record Official record
Conditions
Fatigue, Febrile Neutropenia, Solid Neoplasm
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 11, 2026, 2:10 AM EDT
Not listed Phase 3 Interventional

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

NCT00020865
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cefepime hydrochloride, levofloxacin
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 11, 2026, 2:10 AM EDT
Terminated No phase listed Observational Results available

Fluoroquinolone Resistance Prevalence Study

NCT05824689
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 11, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 11, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

NCT00056381
View directory record Official record
Conditions
Neutropenia
Interventions
Anidulafungin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 11, 2026, 2:10 AM EDT
Completed No phase listed Observational

Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

NCT03262584
View directory record Official record
Conditions
Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Sep 11, 2026, 2:10 AM EDT
Withdrawn Phase 3 Interventional

Fever and Neutropenia in Pediatric Oncology Patients

NCT03768869
View directory record Official record
Conditions
Fever, Neutropenia
Interventions
Low Risk: Oupatient Management, Low Risk: Inpatient Management, High Risk: Inpatient Management
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 11, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma

NCT00044759
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
Piperacillin/Tazobactam (Tazocin)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
31
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2007 · Synced Sep 11, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

NCT00003739
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 11, 2026, 2:10 AM EDT
Withdrawn Phase 1 Interventional

Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia

NCT00886496
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
recombinant human mannose-binding lectin
Biological
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Sep 11, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

NCT00002742
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
amphotericin B deoxycholate, nystatin
Drug
Lead sponsor
Aronex Pharmaceuticals
Industry
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
59
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Sep 11, 2026, 2:10 AM EDT
Not listed Phase 4 Interventional

Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients

NCT03823950
View directory record Official record
Conditions
Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia, Chemotherapy-Induced Febrile Neutropenia, Pediatric Cancer
Interventions
Granulocyte Colony-Stimulating Factor
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 11, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Results available

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

NCT00911170
View directory record Official record
Conditions
Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions
Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
72
States / cities
Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Sep 11, 2026, 2:10 AM EDT
Completed No phase listed Observational

Use of NGS Cell-free Pathogen Test for Identification of Low Risk Fever & Neutropenia in Pediatric Patients

NCT03530072
View directory record Official record
Conditions
Neutropenia, Fever
Interventions
Karius Test
Diagnostic Test
Lead sponsor
Karius, Inc.
Industry
Eligibility
1 Year to 22 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Sep 11, 2026, 2:10 AM EDT
Completed No phase listed Observational

Determining the Etiology of Febrile Neutropenia Using the Karius Sequencing-based Infectious Disease Diagnostic Assay

NCT02912117
View directory record Official record
Conditions
Infection, Neutropenia
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 11, 2026, 2:10 AM EDT
Terminated Phase 3 Interventional Results available

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

NCT01216241
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
Daptomycin, Saline Placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Sep 11, 2026, 2:10 AM EDT
Not listed Not applicable Interventional

Remote Temperature Monitoring of Adult Subjects Undergoing Outpatient Stem Cell Transplant or CAR-T Cell Therapy

NCT05576220
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
IDION iTempShield
Device
Lead sponsor
IDION Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 11, 2026, 2:10 AM EDT
Active, not recruiting Phase 2 Interventional

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

NCT03078010
View directory record Official record
Conditions
Intestinal Microbiome, Febrile Neutropenia
Interventions
Piperacillin-tazobactam, cefepime
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 11, 2026, 2:10 AM EDT
Completed Phase 1 Interventional

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

NCT00001790
View directory record Official record
Conditions
Fever, Mycoses, Neutropenia
Interventions
FK463
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 11, 2026, 2:10 AM EDT
Completed Phase 3 Interventional

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

NCT00035425
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2009 · Synced Sep 11, 2026, 2:10 AM EDT